NCT00357591终止不适用
MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Alive, Number of days out of the hospital, not on mechanical assistance over 35 day period.
研究概览
简要总结
The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow augmentation or CAFA, improves hemodynamics in heart failure patients. The clinical impact of the hemodynamic improvement is currently being evaluated to determine the effects of CAFA on stopping or reversing the progression of heart failure through three physiological effects:
- VASCULAR - Reducing systemic vascular resistance
- RENAL - Improving renal function
- CARDIAC - Reducing cardiac workload
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients hospitalized due to decompensated heart failure who require IV inotropic and/or vasodilator and diuretic therapy
- •Patients receiving appropriate medical therapy for heart failure, defined as ACE inhibitors and beta blockers (all unless not tolerated or contraindicated) and diuretics, for 1 month prior to study entry
- •For at least 24 hours prior to inclusion into the study, the patient should be treated with a minimum dose of the following: dobutamine 2.5μg/kg/min or milrinone 0.3μg/kg/min or dopamine 5μg/kg/min. or nesiritide 0.01μg/kg/min or nitroglycerin 0.3 µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with diuretic therapy. Doses of the above stated medications should be stable for 6 hours prior to inclusion into study. An increase in this dosage within the first 8 hours after enrollment is determined by the attending physician to be unlikely and the following definition of "not responding adequately to IV inotropic and/or vasodilator and diuretic therapy" is exhibited:
- •PCWP is ≥ 20 mmHg at time of randomization and PCWP was ≥ 18 mmHg continuously for 24 hours or PCWP ≥ 20 mmHg continuously for 12 hours prior to randomization.
- •Cardiac Index < 2.4 L/min/m2
- •There is evidence for abnormal renal function and/or diuretic resistance defined as: Serum creatinine > 1.2 mg/dL or Diuretic dosage of intravenous Furosemide ≥ 120 mg daily, or equivalent
- •LVEF < 35%
- •Male or female 18-90 years of age
- •If female, no child-bearing potential or negative pregnancy test
- •Written informed consent
- •Willingness to participate in required follow-up exams
排除标准
- •Acute Q-wave myocardial infarction within past 7 days
- •Post cardiotomy shock within past 30 days
- •Cardiac surgery within past 14 days
- •Bridge to transplant
- •History of severe COPD as defined as FEV1 < 1.0 liter
- •History of malignant arrhythmias defined as either:
- •sustained ventricular tachycardia > 15 beats or more in length, not associated with a correctable cause, within the preceding 3 months, unless the patient presently has an implantable cardiac defibrillator.
- •history of ventricular fibrillation or sudden death, unless the patient presently has an implantable cardiac defibrillator
- •Patients implanted with a resynchronization device within the previous 14 days or if there is a possibility of implant within 60 days following randomization
- •Systolic pressure <80 mmHg
- •Requiring cardiopulmonary support type devices
- •Platelets < 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the absence of anticoagulation therapy.
- •Infection (WBC ≥ 12.5 x 103/ml, and or temperature ≥ 100.5°F/38°C)
- •History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within the last 3 months
- •Unwilling or unable to receive blood transfusion
- •Inability to undergo treatment with heparin
- •Patients on dialysis or serum creatinine > 4.0 mg/dl
- •Primary liver disease with bilirubin, SGOT, or SGPT > 4X upper limit of normal
- •Life expectancy from other disease < 12 months
- •Patients who are active on the cardiac transplantation waiting list, unless there is a documented reason (large body habitus, highly sensitized, O blood group) to anticipate that transplant is unlikely within the subsequent 65 days.
- •Symptomatic patent foramen ovale or intracardiac shunt
- •Patients diagnosed with clinically significant peripheral vascular disease, defined as absent pedal pulse or signs or symptoms of limb ischemia, including a history of intermittent claudication
- •Patients with amyloidosis, thyroid induced heart failure, high output failure secondary to an arterio-venous fistula, and significant uncorrected primary valvular disease (with the exception of mitral regurgitation believed secondary to LV dilatation)
结局指标
主要结局
Alive, Number of days out of the hospital, not on mechanical assistance over 35 day period.
时间窗: 35 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
FiH Safety and Feasibility Study Assessing Intra-articular Administration of aeGF in Patients With Knee OsteoarthritisOsteoarthritis, KneeNCT06690710Scarcell Therapeutics S.A.S.15
已完成
1 期
A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy SubjectsCicatrix, HypertrophicNCT03569267Olix Pharmaceuticals, Inc.48
已完成
2 期
A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1StudyBrain cancerGMB10029211NL-OMON49405TELIX International Pty Ltd2
终止
不适用
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)Radiographic Contrast Agent NephropathyNCT01168024Osprey Medical, Inc16
已完成
3 期
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT05816057Hangzhou Jiuyuan Gene Engineering Co. Ltd.,476